PHOXILIUM

This brand name is authorized in Austria, Brazil, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Lithuania, Malta, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom

Active ingredients

The drug PHOXILIUM contains a combination of these active pharmaceutical ingredients (APIs):

1 Calcium chloride
UNII M4I0D6VV5M - CALCIUM CHLORIDE

Calcium is the most abundant mineral in the body, and is an essential body electrolyte. Homeostasis is mainly regulated by the parathyroid hormone, by calcitonin, and by the activated form of vitamin D. Calcium is a structural component of bones and teeth. It is also required for blood clotting, neurotransmitter release, muscle contraction and normal heartbeat.

Read about Calcium chloride
2 Potassium chloride
UNII 660YQ98I10 - POTASSIUM CHLORIDE

Potassium plays a vital physiological role in maintenance of normal electrical excitability of nerve and muscle. It is also important in the genesis and correction of imbalances of acid-base metabolism.

Read about Potassium chloride
3 Magnesium chloride
UNII 02F3473H9O - MAGNESIUM CHLORIDE
Read about Magnesium chloride
4 Sodium chloride
UNII 451W47IQ8X - SODIUM CHLORIDE

Sodium chloride is the principle salt involved in maintaining the osmotic tension of blood and tissues. Changes in osmotic tension influence the movement of fluids and diffusion of salts in cellular tissue.

Read about Sodium chloride
5 Sodium bicarbonate
UNII 8MDF5V39QO - SODIUM BICARBONATE

Sodium bicarbonate has antacid properties. Sodium bicarbonate causes neutralisation of gastric acid with the production of carbon dioxide.

Read about Sodium bicarbonate
6 Sodium phosphate
UNII 22ADO53M6F - SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Read about Sodium phosphate

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
PHOXILIUM Solution for haemodialysis / haemofiltration Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
B05ZB Hemofiltrates B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05Z Hemodialytics and hemofiltrates
Discover more medicines within B05ZB

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 503220110030707
Country: EE Ravimiamet Identifier(s): 1334786
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 71309
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 133384
Country: FR Base de données publique des médicaments Identifier(s): 64119056
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 324870
Country: HK Department of Health Drug Office Identifier(s): 61168
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1029981
Country: MT Medicines Authority Identifier(s): MA1277/03001
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 15830
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100222810
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W66877001, W66877002, W66877003, W66877004
Country: SG Health Sciences Authority Identifier(s): 15730P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8681413881466

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.